Abstract:Spherical crystallization is widely employed in pharmaceutical industry to produce spherical particles that exhibit improved micrometric performances of active pharmaceutical ingredients (APIs), including particle size, morphology, flowability, and compressibility. Especially for APIs with poor powder performance and low solubility, spherical co-crystallization offers the potential to enhance both dissolution properties and tablet manufacturability by combining the API and cocrystal coformer (CCF) into a spherical particle. In this study, we aimed to enhance the physicochemical properties of carbamazepine (CBZ) and hesperetin (HPE) by synthesizing a novel cocrystal with the stoichiometric ratio of 1:1. Crystal structure of the CBZ-HPE cocrystal was determined using single crystal X-ray diffraction (SCXRD). To further improve the poor powder performances such as low flowability and compressibility resulting from the needle morphology of the cocrystals, we designed three spherical crystallization strategies: common spherical agglomeration, oil-out-induced spherical agglomeration and spherulitic growth method. The spherical particles of CBZ-HPE cocrystals were characterized by powder X-ray diffraction (PXRD), polarized light microscopy (PLM), differential scanning calorimetry (DSC), scanning electron microscopy (SEM), thermogravimetric analysis (TGA), particle size instrumentation, and Fourier transform infrared spectroscopy (FTIR) to provide information about crystal structure, particle morphology, particle size and circularity distribution. The results revealed significant differences in particle morphology, flowability, particle size and dissolution rate among the various spherical crystallization strategies. Theoretical calculations elucidated three spherical crystallization mechanisms: spherical agglomeration (SA), oil-out-induced spherical agglomeration (OOSA) and spherulite growth (SG). This study offers both experimental and theoretical foundations for the application of different spherical crystallization techniques in the pharmaceutical industry.

New Method for Determination of Omeprazole Enteric-coated Pellets Relative Sphericity

Preparation of esomeprazole magnesium enteric-coated pellets by extrusion spheronization

Bridging the structure gap between pellets in artificial dissolution media and in gastro-intestinal tract in rats

The structural diversity of ibuprofen sustained-release pellets on the same goal of bioequivalence consistency

Preparation and Characterization of a Novel Aqueous Dispersion for Enteric Coating of Pantoprazole Sodium Pellets

Preparation and Quality Evaluation of a Novel Multi-Unit Dosage Form by Compaction of Enteric Pellets

DEM-DDM Investigation of the Tablet Coating Process Using Different Particle Shape Models

Preparation of isosorbide-5-mononitrate pellets by extrusion/spheronization and study on its properties

Bile Salt/phospholipid Mixed Micelle Precursor Pellets Prepared by Fluid-Bed Coating

Could the Change of Excipient Content Improve the Stability of Gastroresistant Omeprazole Pellets?

Preparation and Evaluation of Duloxetine Hydrochloride Enteric-Coated Pellets with Different Enteric Polymers

Measuring Bismuth Oxide Particle Size and Morphology in Film-Coated Tablets

Quantitative Analysis of Uncoated Eszopiclone Tablets by Near-Infrared Spectroscopy

[Preparation of Pantoprazole Sodium Enteric-Coated Pellets-Type Tablets].

Preparation of Sustained-Release and Enteric Coated Pellets of Pantoprazole

Content determination of esomeprazole in bulk drug by HPLC

Comparison study of different spherical crystallization methods of ambroxol hydrochloride

Sustainable preparation of spherical particles of novel carbamazepine-hesperetin cocrystal via different crystallization strategies: From mechanism to application

Determination of omeprazole in human plasma by liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry.

Preparation and in Vitro Release Study of Sustained-release Coated Pellets Containing Clarithromycin

Determination related substances of rabeprazole sodium enteric-coated pellets by HPLC